HK1039570B - Contulakin-g、其類似物以及其使用 - Google Patents

Contulakin-g、其類似物以及其使用

Info

Publication number
HK1039570B
HK1039570B HK02101114.7A HK02101114A HK1039570B HK 1039570 B HK1039570 B HK 1039570B HK 02101114 A HK02101114 A HK 02101114A HK 1039570 B HK1039570 B HK 1039570B
Authority
HK
Hong Kong
Prior art keywords
contulakin
peptide
disorders
sub
precursor
Prior art date
Application number
HK02101114.7A
Other languages
English (en)
Other versions
HK1039570A1 (en
Inventor
Grey Craig A
Griffin David
M Olivera Baldomero
Watkins Maren
R Hillyard David
Imperial Julita
J Cruz Lourdes
D Wagstaff John
T Layer Richard
M Jones Robert
Tyler Mccabe R
Original Assignee
Cognetix Inc
Univ Utah Res Found
Salk Inst Biological Studies
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cognetix Inc, Univ Utah Res Found, Salk Inst Biological Studies filed Critical Cognetix Inc
Publication of HK1039570A1 publication Critical patent/HK1039570A1/xx
Publication of HK1039570B publication Critical patent/HK1039570B/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K9/00—Peptides having up to 20 amino acids, containing saccharide radicals and having a fully defined sequence; Derivatives thereof
    • C07K9/001—Peptides having up to 20 amino acids, containing saccharide radicals and having a fully defined sequence; Derivatives thereof the peptide sequence having less than 12 amino acids and not being part of a ring structure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Vascular Medicine (AREA)
  • Psychology (AREA)
  • Zoology (AREA)
  • Endocrinology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Urology & Nephrology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Diabetes (AREA)
  • Addiction (AREA)
  • Hematology (AREA)
  • Hospice & Palliative Care (AREA)
  • Orthopedic Medicine & Surgery (AREA)
HK02101114.7A 1998-10-20 2002-02-15 Contulakin-g、其類似物以及其使用 HK1039570B (zh)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US10501598P 1998-10-20 1998-10-20
US12856199P 1999-04-09 1999-04-09
US13066199P 1999-04-23 1999-04-23
PCT/US1999/024380 WO2000023092A1 (en) 1998-10-20 1999-10-20 Contulakin-g, analogs thereof and uses therefor

Publications (2)

Publication Number Publication Date
HK1039570A1 HK1039570A1 (en) 2002-05-03
HK1039570B true HK1039570B (zh) 2004-10-15

Family

ID=27379856

Family Applications (1)

Application Number Title Priority Date Filing Date
HK02101114.7A HK1039570B (zh) 1998-10-20 2002-02-15 Contulakin-g、其類似物以及其使用

Country Status (10)

Country Link
US (6) US6369193B1 (zh)
EP (1) EP1123109B1 (zh)
JP (2) JP2002527093A (zh)
AT (1) ATE250627T1 (zh)
AU (1) AU766294B2 (zh)
CA (1) CA2347713C (zh)
DE (1) DE69911632T2 (zh)
ES (1) ES2207970T3 (zh)
HK (1) HK1039570B (zh)
WO (1) WO2000023092A1 (zh)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6369193B1 (en) * 1998-10-20 2002-04-09 University Of Utah Research Foundation Contulakin-G, analogs thereof and uses therefor
US20060019892A1 (en) * 2003-03-05 2006-01-26 Florida Atlantic University Conopeptides and methods of use
WO2004078779A2 (en) * 2003-03-05 2004-09-16 Florida Atlantic University Conopeptides and methods of use
US20090062211A1 (en) * 2003-03-05 2009-03-05 Florida Atlantic University Conopeptides and methods of use
WO2009071097A1 (en) * 2007-12-05 2009-06-11 Neurokey A/S Use of hypothermia inducing drugs
EP2838913A4 (en) * 2012-04-17 2015-12-02 Univ Utah Res Found CONOPEPTIDES AND ANALOGS HAVING ACTION ON SODIUM CHANNELS, ASSOCIATED COMPOSITIONS AND ASSOCIATED METHODS
EP2896402A1 (en) * 2014-01-20 2015-07-22 Vect-Horus Activated neurotensin molecules and the uses thereof
GB201603510D0 (en) * 2016-02-29 2016-04-13 Univ Ulster Compositions for use in the treatment of neurological disease

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US587454A (en) * 1897-08-03 Peter renk
US4447356A (en) * 1981-04-17 1984-05-08 Olivera Baldomero M Conotoxins
SG50624A1 (en) * 1991-12-30 1998-07-20 Neurex Corp Methods of producing analgesia and enhancing opiate analgesia
US5432155A (en) * 1993-06-29 1995-07-11 The Salk Institute For Biological Studies Conotoxins I
US6369193B1 (en) * 1998-10-20 2002-04-09 University Of Utah Research Foundation Contulakin-G, analogs thereof and uses therefor

Also Published As

Publication number Publication date
CA2347713A1 (en) 2000-04-27
JP2011024579A (ja) 2011-02-10
ATE250627T1 (de) 2003-10-15
EP1123109B1 (en) 2003-09-24
US6696408B1 (en) 2004-02-24
WO2000023092A1 (en) 2000-04-27
ES2207970T3 (es) 2004-06-01
US6489298B1 (en) 2002-12-03
US20040072758A1 (en) 2004-04-15
DE69911632T2 (de) 2004-04-29
US6369193B1 (en) 2002-04-09
EP1123109A4 (en) 2002-03-06
AU766294B2 (en) 2003-10-16
CA2347713C (en) 2010-07-13
US6344551B1 (en) 2002-02-05
WO2000023092A9 (en) 2002-08-22
JP2002527093A (ja) 2002-08-27
HK1039570A1 (en) 2002-05-03
AU6520399A (en) 2000-05-08
EP1123109A1 (en) 2001-08-16
US20050203003A1 (en) 2005-09-15
DE69911632D1 (de) 2003-10-30

Similar Documents

Publication Publication Date Title
HK1039570A1 (en) Contulakin-g, analogs thereof and uses therefor
BR9909925A (pt) Compostos, composições farmacêuticas, e, processos para a fabricação de um composto, e de tratamento de um mamìfero sofrendo de doenças resultantes da autoimunidade e inflamação patológica
NZ299340A (en) Use of tricyclic benzazepines such as vasopressin to treat congestive heart failure and renal disease
BR0111562A (pt) Análogos de peptìdeo 1 semelhantes ao glucagon
BR9912109A (pt) Compostos, composições farmacêuticas, processo para a manufatura de um composto, e, método de tratar um mamìfero sofrendo de inflamação patológica e autoimunidade
GC0000375A (en) Benzodiazepine derivatives as gaba a receptor modulators
AU2808495A (en) Phosphonic acid compounds, their production and use
EE200100097A (et) Hingamisteede lima tootmise tõkestamine EGF-R antagonistide manustamise teel
NO20021721L (no) C-aryl-glukosid-SGLT2-inhibitorer
BG105205A (en) Biphenyl sulfonamides as dual angiotensin endothelin receptor antagonists
IL120266A (en) Use of estrogen antagonists and estrogen agonists in the preparation of medicaments for inhibiting pathological conditions
BR0004208A (pt) Sequências de nucleotìdeos codificando gene pgi
ES2135934T3 (es) Compuesto eventualmente bajo la forma de isomero optico puro o de mezcla de tales isomeros.
CN101133037A (zh) 六元杂环化合物及其用途
YU41199A (sh) Hinoksalindioni
BE2014C034I2 (en) Derivatives of 3-(2-oxo- 1,3']bipyrrolidinyl-3-ylidenemethyl)-cephems
CA2443285A1 (en) Use of (z)-2-cyano-3-hydroxy-but-2-enoic acid-(4'-trifluoromethylphenyl)-amide for treating multiple sclerosis
IL132690A0 (en) Prostaglandin pharmaceutical compositions
NO971789L (no) Di-tert-butylfenolforbindelser med heterocyklisk enhet for anvendelse som antiinflammatoriske midler
CA2361605A1 (en) Pyrimidine-2,4,6-triones as inhibitors of matrix metalloproteinases
CA2213810A1 (en) Benzo¬b|thiophene compounds, intermediates, processes, compositions and methods
PT980354E (pt) Analogos de vitamina d3 com cadeias laterais bis-c-20
KR970074764A (ko) 불소화된 비타민 d₃ 동족체
JP2002527093A5 (zh)
WO2002011704A3 (en) Use of aryl-substituted 1,1-diphosphonates for the treatment of bone diseases

Legal Events

Date Code Title Description
CHRG Changes in the register

Free format text: CORRECTION OF THE NAME OF THE APPLICANT FROM SALK INSTITUTE TO THE SALK INSTITUTE FOR BIOLOGICAL STUDIES

PF Patent in force
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20141020